Sovran Advisors, LLC Summit Therapeutics Inc. Transaction History
Sovran Advisors, LLC
- $702 Billion
- Q4 2024
A detailed history of Sovran Advisors, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Sovran Advisors, LLC holds 117,174 shares of SMMT stock, worth $2.74 Million. This represents 0.28% of its overall portfolio holdings.
Number of Shares
117,174Holding current value
$2.74 Million% of portfolio
0.28%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
203Shares Held
76.2MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$571 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$256 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$185 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$127 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$81.1 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.7B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...